Stock listing

Lang & Schwarz:A1436W Wave Life Sciences Ltd. Aktie

German listing (Lang & Schwarz) of Wave Life Sciences Ltd. · home listing NASDAQ:WVE

Follow Wave Life Sciences Ltd. into a list and get an email when it puts out news.

Home listing price · NASDAQ:WVE

$2.56 USD -0.21 (-7.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:WVE

Past year -62.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.55 – $2.79 USDNov 20, 2026
Volume
2.28M sharesNov 20, 2026
Market cap
$504.9M USDAt the close on Nov 20, 2026 · price × 197.2M shares outstanding
52-week range
$2.55 – $21.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$12.25M USDMedian day 2.95M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Wave Life Sciences Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:WVE · Home$2.56 USD-0.21 (-7.6%)2,279,709$2.65$2.79$2.545$2.77Close on Nov 20, 2026
Frankfurt:1U5€2.30 EUR-0.07 (-3.0%)—€2.27€2.30€2.27€2.37Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:WVE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.56-0.21-7.6%$2.65$2.79$2.5452,279,709
$2.77-0.07-2.5%$2.85$2.94$2.752,206,560
$2.84-0.03-1.0%$2.81$2.915$2.772,780,153
$2.87-0.26-8.3%$3.08$3.15$2.8552,321,398
$3.13-0.025-0.8%$3.12$3.195$3.002,656,161
$3.155-0.265-7.7%$3.45$3.53$3.152,462,991
$3.42+0.01+0.3%$3.49$3.49$3.381,704,598
$3.41-0.07-2.0%$3.40$3.558$3.3211,400,159
$3.48+0.115+3.4%$3.42$3.565$3.283,934,545
$3.365+0.145+4.5%$3.25$3.42$3.232,204,914
$3.22-0.40-11.0%$3.59$3.615$3.185,317,219
$3.62+0.04+1.1%$3.70$3.78$3.562,738,498
$3.58+0.06+1.7%$3.55$3.665$3.553,827,068
$3.52-0.07-1.9%$3.64$3.69$3.431,941,203
$3.59-0.04-1.1%$3.62$3.70$3.433,327,320
$3.63-0.01-0.3%$3.75$3.86$3.603,571,422
$3.64+0.19+5.5%$3.44$3.765$3.364,257,137
$3.45+0.24+7.5%$3.50$3.55$3.2354,191,258
$3.21+0.03+0.9%$3.17$3.235$3.133,224,124
$3.18-0.17-5.1%$3.33$3.34$3.122,655,200
$3.35-0.02-0.6%$3.36$3.43$3.341,846,400
$3.37-0.05-1.5%$3.42$3.48$3.352,172,900
$3.42+0.25+7.9%$3.18$3.49$3.183,615,900
$3.17+0.04+1.3%$3.15$3.19$3.081,863,500
$3.13-0.06-1.9%$3.24$3.28$3.083,281,800
$3.19+0.10+3.2%$3.13$3.23$3.083,351,000
$3.09-0.05-1.6%$3.09$3.13$3.042,824,900
$3.14-0.14-4.3%$3.27$3.27$3.074,183,400
$3.28-0.18-5.2%$3.46$3.46$3.272,256,900
$3.46-0.01-0.3%$3.49$3.53$3.431,655,800
$3.47-0.07-2.0%$3.48$3.51$3.372,664,300
$3.54+0.02+0.6%$3.48$3.60$3.433,052,600
$3.52-0.23-6.1%$3.78$3.82$3.483,448,600
$3.75-0.03-0.8%$3.81$3.88$3.713,513,200
$3.78-0.10-2.6%$3.89$3.96$3.773,743,700
$3.88+0.18+4.9%$3.95$4.07$3.785,410,200
$3.70+0.06+1.6%$3.79$3.84$3.624,209,300
$3.64-0.03-0.8%$3.67$3.78$3.562,765,400
$3.67-0.11-2.9%$3.77$3.78$3.603,546,400
$3.78-0.18-4.5%$4.00$4.00$3.754,066,600
$3.96+0.01+0.3%$3.96$4.01$3.823,155,600
$3.95-0.40-9.2%$4.27$4.35$3.923,972,900
$4.35+0.09+2.1%$4.30$4.43$4.222,577,900
$4.26-0.09-2.1%$4.44$4.45$4.202,372,500
$4.35-0.09-2.0%$4.42$4.48$4.314,409,700
$4.44-0.07-1.6%$4.59$4.65$4.422,171,800
$4.51+0.05+1.1%$4.55$4.60$4.422,990,700
$4.46-0.12-2.6%$4.58$4.58$4.402,466,800
$4.58-0.01-0.2%$4.60$4.63$4.492,869,900
$4.59-0.08-1.7%$4.67$4.72$4.562,207,600
$4.67-0.14-2.9%$4.76$4.76$4.632,767,600
$4.81-0.10-2.0%$4.86$4.93$4.763,248,700
$4.91+0.05+1.0%$4.86$4.97$4.753,557,700
$4.86+0.16+3.4%$4.71$4.89$4.653,030,000
$4.70-0.18-3.7%$4.80$4.97$4.656,156,700
$4.88-0.09-1.8%$4.95$5.09$4.665,478,900
$4.97+0.07+1.4%$4.85$4.98$4.803,000,400
$4.90-0.14-2.8%$5.06$5.07$4.843,811,600
$5.04-0.12-2.3%$5.16$5.22$5.032,250,700
$5.16-0.07-1.3%$5.23$5.28$5.042,949,800
$5.23-0.02-0.4%$5.26$5.30$5.182,197,200
$5.25+0.13+2.5%$5.12$5.35$5.122,413,500
$5.12-0.17-3.2%$5.27$5.32$5.124,554,700
$5.29+0.04+0.8%$5.30$5.48$5.272,721,900
$5.25-0.17-3.1%$5.41$5.47$5.182,660,500
Ticker
Lang & Schwarz:A1436W
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Wave Life Sciences Ltd. news

Wave Life Sciences Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 178 in all · newest Nov 13, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest Oct 27, 2026
Decks
98 decks · latest Nov 9, 2026

Where Wave Life Sciences Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:WVE · Home listingNASDAQUnited StatesUSD
gettex:1U5gettexGermanyEUR
LS Exchange:A1436WLS ExchangeGermanyEUR
Tradegate:1U5TradegateGermanyEUR
BOATS:WVEBOATSUnited StatesUSD
Lang & Schwarz:A1436W · This pageLang & SchwarzGermanyEUR
Stuttgart:1U5StuttgartGermanyEUR
Frankfurt:1U5FrankfurtGermanyEUR
Dusseldorf:1U5DusseldorfGermanyEUR
Hamburg:1U5HamburgGermanyEUR
Munich:1U5MunichGermanyEUR

Valuation

EV/sales 1.1× against a median of 16.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$74.16M USD
P/E
Loss
EV/sales
1.1×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.3×
Gross margin
Not reported
Operating margin
−320.9%
Net margin
−296.9%
Debt to equity
0.0×
Beta vs S&P 500
1.70

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Wave Life Sciences Ltd. · NASDAQ:WVEUS$504.9MUS$74.16Mn/a1.1×n/a1.3×−296.9%0.0×1.70
Abbisko Cayman Limited · HKEX:2256US$518.9MUS$228.0Mn/an/an/a1.6×n/a0.2×n/a
Alumis Inc. · NASDAQ:ALMSUS$512.6MUS$116.5Mn/a16.1×n/a1.4×n/a0.1×1.58
Electra Therapeutics, Inc. · NASDAQ:ETRAUS$509.8MUS$107.3Mn/an/an/a1.3×n/a0.0×n/a
Adlai Nortye Group Ltd. · NASDAQ:ANLUS$502.2MUS$297.0Mn/a59.4×n/a2.3×−710.6%0.1×1.96
Steminent Biotherapeutics, Inc. · TPEX:7729US$496.9MUS$470.4Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.1Mn/a23.2×n/a2.2×−200.8%0.0×n/a
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.6Mn/an/an/a5.0×n/a0.1×n/a
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
Median of the othersUS$496.1MUS$293.0M16.1×2.3×−455.7%0.1×1.60

Forecasts

17 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
17.05 USD · Analysts' mean
EPS, year to Dec 2026
-1.10 · 15 analysts
Revenue, year to Dec 2026
62.97M · 18 analysts

Team and board

Officers

OfficerRole
Adrian RawcliffeCEO-Partner and Chief Executive Officer
Christian HenryPresident and Chief Executive Officer, Pacific Biosciences
Paul BolnoPresident and Chief Executive Officer
Linda RockettSenior Vice President, General Counsel
James SaliernoDirector, Investor Relations
Kate RauschVP, Corporate Affairs and Investor Relations
Aik Na TanSenior Vice President (Administration), Nanyang Technological University, Singapore
Daryn LewisSenior Vice President, Head of Human Resources
Ginnie YangSenior Vice President, Translational Medicine
Sridhar VaddeboinaSenior Vice President, Chemistry, Manufacturing, and Controls
Monika VnukChief Business Officer

Board

DirectorRole
Ken TakanashiVice Chairman

Events

Calls

CallWhenStatus
Wave Life Sciences (NASDAQ:WVE) Q3 2026 Earnings CallTue, Oct 27, 2026 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q2 2026 Earnings CallThu, Jul 30, 2026 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q1 2026 Earnings CallTue, Apr 28, 2026 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q4 2025 Earnings CallThu, Feb 26, 2026 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q3 2025 Earnings CallMon, Nov 10, 2025 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q2 2025 Earnings CallWed, Jul 30, 2025 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q1 2025 Earnings CallThu, May 08, 2025 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q4 2024 Earnings CallTue, Mar 04, 2025 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:30 AM ETReplay
All 25 calls
CallWhenStatus
Wave Life Sciences (NASDAQ:WVE) Q1 2024 Earnings CallThu, May 09, 2024 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q4 2023 Earnings CallWed, Mar 06, 2024 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q3 2023 Earnings CallThu, Nov 09, 2023 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q2 2023 Earnings CallThu, Aug 03, 2023 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q1 2023 Earnings CallWed, May 03, 2023 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q4 2022 Earnings CallWed, Mar 22, 2023 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q3 2022 Earnings CallThu, Nov 10, 2022 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q1 2022 Earnings CallThu, May 12, 2022 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q4 2021 Earnings CallThu, Mar 03, 2022 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q1 2021 Earnings CallThu, May 13, 2021 · 8:30 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q4 2020 Earnings CallThu, Mar 04, 2021 · 8:00 AM ETReplay
Wave Life Sciences (NASDAQ:WVE) Q3 2020 Earnings CallMon, Nov 09, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 27, 2026 · Before open+7.5%
Q2 2026Jul 30, 2026 · Before open−0.9%
Q1 2026Apr 28, 2026 · Before open+8.4%
Q4 2025Feb 26, 2026−4.2%
Q3 2025Nov 10, 2025 · Before open−10.3%
Q2 2025Jul 30, 2025 · Before open−1.9%
Q1 2025May 8, 2025 · Before open+0.8%
Q4 2024Mar 4, 2025+5.2%
Q3 2024Nov 12, 2024 · Before open−3.4%
Q2 2024Aug 8, 2024 · Before open−4.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · Before open−2.4%
Q4 2023Mar 6, 2024 · Before open+31.3%
Q3 2023Nov 9, 2023 · Before open−9.6%
Q2 2023Aug 3, 2023 · Before open+15.8%
Q1 2023May 3, 2023 · Before open+1.9%
Q4 2022Mar 22, 2023 · Before open−10.4%
Q3 2022Nov 10, 2022 · Before open+5.8%
Q2 2022Aug 11, 2022 · Before open+16.9%
Q1 2022May 12, 2022 · Before open−12.2%
Q4 2021Mar 3, 2022 · Before open−2.9%

Open Events

Decks

DeckKindSlidesDate
AASLD 2026Conference16 slidesNov 9, 2026
Investor Presentation (July 2026)Investor deck50 slidesJul 30, 2026
ATS 2026Conference19 slidesMay 18, 2026
Investor Presentation (February 2026)Investor deck49 slidesFeb 26, 2026
Investor Presentation (January 2026)Investor deck62 slidesJan 12, 2026
Investor Presentation (November 2025)Investor deck58 slidesNov 17, 2025
ObesityWeek 2025Conference21 slidesOct 31, 2025
Investor Presentation (September 2025)Investor deck49 slidesSep 24, 2025
Investor Presentation (August 2025)Investor deck45 slidesAug 5, 2025
85th American Diabetes Association Scientific Sessions (ADA 2025)Conference14 slidesJun 20, 2025
Show 50 decks
DeckKindSlidesDate
32nd European Congress on Obesity, ECO2025 (May 2025)Conference16 slidesMay 13, 2025
Investor Presentation (May 2025)Investor deck43 slidesMay 8, 2025
Investor Presentation (March 2025)Investor deck36 slidesMar 4, 2025
20th Annual HD Therapeutics Conference (February 2025)Conference17 slidesFeb 25, 2025
Investor Presentation (January 2025)Investor deck31 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck38 slidesNov 20, 2024
Investor Day (October 2024)Investor day89 slidesOct 30, 2024
Investor Presentation (October 2024)Investor deck38 slidesOct 1, 2024
2024 EHDN Plenary Meeting & Enroll-HD CongressConference16 slidesSep 13, 2024
Investor Presentation (August 2024)Investor deck36 slidesAug 8, 2024
MENA 2024Conference12 slidesMay 19, 2024
American Society for Gene & Cell Therapy 27th Annual Meeting (May 2024)Conference15 slidesMay 10, 2024
Investor Presentation (May 2024)Investor deck42 slidesMay 9, 2024
Investor Presentation (March 2024)Investor deck41 slidesMar 6, 2024
Deaminet 2024Conference20 slidesJan 19, 2024
Investor Presentation (January 2024)Investor deck40 slidesJan 8, 2024
Investor Presentation (December 2023)Investor deck43 slidesDec 15, 2023
Investor Presentation (November 2023)Investor deck55 slidesNov 9, 2023
Investor Presentation (October 2023)Investor deck56 slidesOct 2, 2023
Investor Presentation (September 2023)Investor deck32 slidesSep 5, 2023
26th Annual ASGCT Meeting 2023Conference13 slidesMay 17, 2023
26th Annual ASGCT Meeting 2023Conference15 slidesMay 17, 2023
Investor Presentation (May 2023)Investor deck34 slidesMay 3, 2023
Investor Presentation (January 2023)Investor deck68 slidesJan 9, 2023
Merger or Acquisition (December 2022)Merger or acquisition5 slidesDec 13, 2022
Investor Presentation (November 2022)Investor deck63 slidesNov 15, 2022
18th Annual Meeting of the Oligonucleotide Therapeutics Society (October 2022)Conference12 slidesOct 5, 2022
18th Annual Meeting of the Oligonucleotide Therapeutics Society (October 2022)Conference24 slidesOct 4, 2022
Investor Presentation (October 2022)Investor deck63 slidesOct 4, 2022
IRT 3NA 2022Conference13 slidesAug 28, 2022
Investor Presentation (August 2022)Investor deck54 slidesAug 17, 2022
ENCALS Meeting 2022Conference15 slidesJun 3, 2022
Investor Presentation (May 2022)Investor deck63 slidesMay 12, 2022
TIDES US 2022Conference18 slidesMay 2022
Oligonucleotides & Precision Therapeutics, March 15-16, 2022Conference17 slidesMar 15, 2022
Technical Presentation (March 2022)Technical16 slidesMar 3, 2022
Investor Presentation (March 2022)Investor deck68 slidesMar 3, 2022
Deaminet 2022Conference14 slidesJan 24, 2022
Investor Presentation (January 2022)Investor deck45 slidesJan 10, 2022
Investor Presentation (November 2021)Investor deck79 slidesNov 10, 2021

This page holds 50 of 98 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Made bigger: about US$350M · US$19 a share · Jefferies +4
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Truist Securities, Mizuho
Dec 9, 2025
At-the-market programme of shares sold under ATM program
Tranche closed: US$72.1M raised
Use of proceeds: Extend expected cash runway into 2Q 2027
Nov 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Nov 10, 2015.

Price
US$16.00 a share
Shares offered
6,375,000 ordinary shares
Offering size
US$102 million
Underwriters' option
Up to 956,250 more shares
Underwriters
Jefferies, Leerink Partners, JMP Securities, SunTrust Robinson Humphrey · In the order on the cover
Shares delivered
On or about Nov 16, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceSep 4, 2015
Filed publiclyOct 9, 2015
Amended 5 timesNewest Nov 10, 2015
Shares registered with an exchangeNov 9, 2015
Declared effective by the SECNov 10, 2015
Final prospectus, with the priceNov 12, 2015

Open IPO · From the cover of the final prospectus (424B1) filed Nov 12, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue42.7M108.3M113.3M3.65M41.0M20.1M16.0M14.4M3.70M1.49M
Research and development182.8M159.7M130.0M115.9M121.9M130.9M175.4M134.4M79.3M40.8M
Operating income-215.4M-110.4M-68.0M-162.7M-127.0M-153.4M-208.3M-159.5M-102.4M-55.7M
Depreciation and amortization3.44M3.90M5.00M6.57M7.48M8.11M7.59M5.58M2.15M784.0K
EBITDA-211.9M-106.5M-63.0M-156.1M-119.5M-145.3M-200.7M-153.9M-100.2M-54.9M
Income before tax-204.4M-97.0M-58.2M-161.1M-122.4M-150.8M-193.6M-146.6M-101.1M-55.2M
Income tax00-677.0K681.0K-204.0K-841.0K069.0K842.0K482.0K
Net income-204.4M-97.0M-57.5M-161.8M-122.2M-149.9M-193.6M-146.7M-102.0M-55.7M
Earnings per share, basic-1.21-0.70-0.54-2.05-2.36-3.82-5.72-5.06-3.85-2.44
Earnings per share, diluted-1.21-0.70-0.54-2.05-2.36-3.82-5.72-5.06-3.85-2.44

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents602.1M302.1M200.4M88.5M150.6M184.5M147.2M174.8M142.5M150.3M
Short-term investments0
Receivables1.28M1.42M21.1M30.0M20.0M10.0M1.00M
Current assets614.8M320.4M235.4M98.5M162.6M230.0M185.5M202.3M150.5M152.0M
Property, plant and equipment7.41M10.1M13.1M17.3M22.3M29.2M36.4M39.9M27.3M8.61M
Total assets638.5M352.2M274.9M146.4M207.0M279.2M284.3M295.9M181.8M164.8M
Accounts payable15.7M16.3M12.8M16.9M7.28M13.8M9.07M13.1M7.60M4.94M
Current liabilities95.1M111.0M186.4M71.5M64.2M121.0M118.2M130.0M18.2M12.2M
Total liabilities112.3M134.8M227.4M183.6M166.6M188.6M212.6M214.7M34.4M22.1M
Shareholders' equity518.4M209.5M39.6M-45.1M32.5M82.8M63.7M73.3M139.6M134.6M
Shares outstanding0153.0M119.2M86.9M59.8M48.8M34.3M29.5M27.8M23.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-187.5M-151.0M-19.4M-127.8M-89.0M-116.0M-188.2M-22.9M-83.7M-31.9M
Capital spending-718.0K-938.0K-1.11M-1.36M-560.0K-1.34M-3.92M-9.94M-18.9M-5.57M
Free cash flow-188.2M-152.0M-20.5M-129.1M-89.6M-117.3M-192.1M-32.8M-102.6M-37.5M
Cash from investing-718.0K-938.0K-1.11M-1.25M-560.0K-1.34M-3.92M-9.94M-18.9M-5.56M
Cash from financing488.2M253.9M132.5M67.2M55.8M154.5M164.4M65.1M94.4M29.1M
Change in cash300.0M101.8M111.9M-62.1M-33.9M37.3M-27.6M32.3M-7.78M-8.38M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
10-Q · Quarterly reportOct 27, 2026Quarterly reportSEC
8-K · Current reportOct 27, 2026ResultsSEC
ARS · Annual report to shareholdersOct 14, 2026Annual reportSEC
DEF 14A · Proxy statementOct 14, 2026Meeting noticeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 11, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
15-12GAug 7, 2026Other filingsSEC
POS AM · Amendment to an effective registrationAug 7, 2026Offer documentSEC
POSASRAug 7, 2026Other filingsSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
S-8 POSAug 7, 2026Offer documentSEC
8-K12BAug 7, 2026Other filingsSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
8-K · Current reportJun 26, 2026Meeting outcomeSEC
8-K · Current reportMay 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
DEF 14A · Proxy statementMay 7, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
UPLOAD · Letter from the SECMay 5, 2026Other filingsSEC
CORRESP · Letter to the SECMay 1, 2026Other filingsSEC
PRER14AMay 1, 2026Other filingsSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
UPLOAD · Letter from the SECApr 30, 2026Other filingsSEC
10-Q · Quarterly reportApr 28, 2026Quarterly reportSEC
8-K · Current reportApr 28, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Current reportSEC
3 · Initial statement of ownershipApr 17, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 17, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 15, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 15, 2026Meeting noticeSEC
8-K · Current reportApr 15, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 30, 2026Big-stake noticeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
8-K · Current reportMar 26, 2026Current reportSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
8-K · Current reportFeb 2, 2026Current reportSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 15, 2025Big-stake noticeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
424B5 · ProspectusDec 10, 2025Offer documentSEC
8-K · Current reportDec 10, 2025Material contractSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
424B5 · ProspectusDec 8, 2025Offer documentSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
8-K · Current reportDec 8, 2025Current reportSEC
8-K · Current reportNov 17, 2025Current reportSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
S-8 · Registration statement for employee plansNov 10, 2025Offer documentSEC
S-8 · Registration statement for employee plansNov 10, 2025Offer documentSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
8-K/A · Current report, amendedOct 30, 2025Current reportSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportSep 24, 2025Current reportSEC
8-K · Current reportSep 3, 2025Current reportSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
8-K · Current reportAug 11, 2025Management or board changeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
8-K · Current reportAug 5, 2025Current reportSEC
10-Q · Quarterly reportJul 30, 2025Quarterly reportSEC
8-K · Current reportJul 30, 2025ResultsSEC
ARS · Annual report to shareholdersJun 23, 2025Annual reportSEC
DEF 14A · Proxy statementJun 23, 2025Meeting noticeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
144 · Notice of proposed saleJun 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-K/A · Annual report, amendedApr 29, 2025Annual reportSEC
8-K · Current reportMar 26, 2025Current reportSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
144 · Notice of proposed saleMar 20, 2025Other filingsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
144 · Notice of proposed saleMar 7, 2025Other filingsSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
10-K · Annual reportMar 4, 2025Annual reportSEC
8-K · Current reportMar 4, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
144 · Notice of proposed saleNov 25, 2024Other filingsSEC
8-K · Current reportNov 20, 2024Current reportSEC
4 · Change in ownershipNov 15, 2024Insider tradeSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 12, 2024Offer documentSEC
S-8 · Registration statement for employee plansNov 12, 2024Offer documentSEC
S-3ASR · Registration statementNov 12, 2024Offer documentSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
144 · Notice of proposed saleNov 8, 2024Other filingsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportOct 30, 2024Current reportSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 18, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
8-K · Current reportOct 16, 2024Current reportSEC
8-K · Current reportOct 15, 2024Current reportSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 1, 2024Big-stake noticeSEC
8-K · Current reportOct 1, 2024Current reportSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
424B5 · ProspectusSep 27, 2024Offer documentSEC
8-K · Current reportSep 26, 2024Material contractSEC
144 · Notice of proposed saleSep 25, 2024Other filingsSEC
424B5 · ProspectusSep 24, 2024Offer documentSEC

This page holds 200 of 745 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Wave Life Sciences Ltd.’s releases · as of Nov 10, 2025

Common shares
197,228,968
Fully diluted
197,228,968

Fully diluted

LineShares
Common shares197,228,968

Share count over time

CountShares
Nov 22, 2026197,228,968

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
PRIMECAP Odyssey Aggressive Growth Fund4.11MUS$22.7MJul 31, 2026
iShares Russell 2000 ETF3.6MUS$20.9MJun 30, 2026
Vanguard Extended Market Index Fund1.75MUS$10.2MJun 30, 2026
Fidelity Growth Company Fund1.66MUS$10.9MMay 31, 2026
Fidelity Small Cap Index Fund1.51MUS$8.31MJul 31, 2026
BlackRock Advantage Small Cap Core Fund1.3MUS$8.54MMay 29, 2026
iShares Russell 2000 Value ETF1.21MUS$7.02MJun 30, 2026
iShares Biotechnology ETF1.19MUS$6.93MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1.19MUS$6.9MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF1.16MUS$6.71MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Extended Market Index Fund751KUS$4.94MMay 31, 2026
Driehaus Small Cap Growth Fund742KUS$4.31MJun 30, 2026
Vanguard Russell 2000 Index Fund718KUS$4.73MMay 31, 2026
North Square Dynamic Small Cap Fund707KUS$4.65MMay 31, 2026
Schwab U.S. Small-Cap ETF703KUS$4.63MMay 31, 2026
Federated Hermes MDT Small Cap Core Fund640KUS$3.52MJul 31, 2026
Fidelity Growth Company K6 Fund470KUS$3.09MMay 31, 2026
iShares Micro-Cap ETF464KUS$2.69MJun 30, 2026
Vanguard Strategic Equity Fund425KUS$2.47MJun 30, 2026
Small Cap Equity Fund414KUS$2.4MJun 30, 2026
iShares U.S. Pharmaceuticals ETF394KUS$2.29MJun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund387KUS$2.25MJun 30, 2026
Dimensional U.S. Small Cap ETF386KUS$2.13MJul 31, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF386KUS$2.24MJun 30, 2026
U.S. Small Cap Portfolio382KUS$2.1MJul 31, 2026
BlackRock Health Sciences Opportunities Portfolio346KUS$2.28MMay 29, 2026
Select Biotechnology Portfolio345KUS$2.27MMay 31, 2026
Vanguard Health Care Index Fund335KUS$2.2MMay 31, 2026
Schwab Small-Cap Index Fund335KUS$1.84MJul 31, 2026
Federated Hermes MDT Small Cap Growth Fund323KUS$1.78MJul 31, 2026
Emerald Growth Fund308KUS$1.7MJul 31, 2026
Emerald Growth Fund308KUS$2.18MApr 30, 2026
SmallCap Growth Fund I305KUS$1.68MJul 31, 2026
U.S. Micro Cap Portfolio285KUS$1.57MJul 31, 2026
Fidelity Total Market Index Fund274KUS$1.8MMay 31, 2026
Fidelity Series Growth Company Fund259KUS$1.7MMay 31, 2026
Master Small Cap Index Series246KUS$1.43MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF246KUS$1.43MJun 30, 2026
Driehaus Micro Cap Growth Fund235KUS$1.36MJun 30, 2026
BlackRock Advantage Small Cap Growth Fund222KUS$1.29MJun 30, 2026
Fidelity Series Total Market Index Fund220KUS$1.45MMay 31, 2026
Vanguard Explorer Fund211KUS$1.16MJul 31, 2026
Column Small Cap Select Fund201KUS$1.32MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF195KUS$1.08MJul 31, 2026
JNL Multi-Manager Small Cap Growth Fund186KUS$1.08MJun 30, 2026
AST Small-Cap Equity Portfolio184KUS$1.07MJun 30, 2026
Nuveen Small Cap Blend Index Fund183KUS$1.01MJul 31, 2026
Fidelity Small Cap Value Index Fund180KUS$1.04MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund170KUS$1.12MMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund157KUS$912KJun 30, 2026

This page holds 50 of 199 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Rawcliffe Adrian
Director
Sale12,700USD 5.29US$67,183Aug 12, 2026
Tan Aik Na
Director
Sale432USD 6.01US$2,596Aug 11, 2026
Takanashi Ken
Director
Sale3,864USD 6.01US$23,223Aug 11, 2026
Wagner Heidi L
Director
Sale7,000USD 6.01US$42,070Aug 11, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Kolchinsky
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past)
Director · Since at least Aug 14, 2015
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Aug 16, 2021
Mark Corrigan
Other companies: Trevena, Inc. (Director · Jul 18, 2023 – Jun 13, 2024 · Past); Novelion Therapeutics Inc (Director · Mar 30, 2017 – Aug 9, 2018 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 2, 2022 · Past); CoLucid Pharmaceuticals Inc (Director · Oct 27, 2015 – Mar 1, 2017 · Past); Avanir Pharmaceuticals Inc (Director · Mar 18, 2014 – Mar 18, 2014 · Past); EPIRUS Biopharmaceuticals Inc (Director · Dec 21, 2009 – Jun 5, 2015 · Past); Cubist Pharmaceuticals Inc (Director · Jun 20, 2008 – Jan 21, 2015 · Past); Sepracor Inc (Executive VP, R&D · Mar 16, 2006 – Oct 20, 2009 · Past)
Director · Since at least Sep 4, 2019
Christian Henry
Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Sep 16, 2021); Pacific Biosciences of California, Inc. (Director · Since at least Jul 27, 2018); CM Life Sciences III Inc. (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Illumina, Inc. (EVP & Chief Commercial Officer · Jun 14, 2013 – Jan 30, 2017 · Past)
President and Chief Executive Officer, Pacific Biosciences · Since at least Nov 10, 2016
Adrian Rawcliffe
Other companies: Adaptimmune Therapeutics PLC (Chief Executive Officer, Director · Jan 1, 2016 – Feb 20, 2025 · Past); Human Genome Sciences Inc (Chief Financial Officer, Director · Jul 30, 2012 – Jul 30, 2012 · Past)
CEO-Partner and Chief Executive Officer · Since at least Feb 1, 2017
Christopher Wright
Other companies: Alkermes plc (Director · Since at least May 24, 2022); Cyclerion Therapeutics, Inc. (Chief Medical Officer · Feb 25, 2021 – Feb 25, 2021 · Past)
Chief Medical Officer · Since at least May 28, 2025
Michael A. Panzara
Other companies: Immunic, Inc. (Chief Medical Officer · Since at least Apr 24, 2026); LeonaBio, Inc. (Director · Since at least Mar 18, 2022)
See Remarks · Feb 1, 2021 – Jul 25, 2022 · Past
Amy Pott
Other companies: enGene Therapeutics Inc. (Chief Global Comm. Ofc. · Since at least May 27, 2025)
Director · Sep 4, 2019 – Aug 18, 2020 · Past
Heidi L. Wagner
Other companies: Alexion Pharmaceuticals Inc (SVP, Global Government Affairs · Oct 1, 2015 – Feb 27, 2018 · Past)
Director · Since at least Sep 4, 2019
Keith Regnante
Other companies: Keros Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Since at least Apr 7, 2020)
Chief Financial Officer · Aug 16, 2016 – Mar 7, 2019 · Past
All 30 people
PersonSeat
Ken Takanashi
Other companies: Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past)
Director · Since at least Aug 14, 2015
Mark Baldry
Other companies: X4 Pharmaceuticals, Inc. (Chief Commercial Officer · Nov 3, 2022 – May 16, 2025 · Past)
Chief Commerical Officer · Aug 5, 2019 – Aug 5, 2019 · Past
Paul B. Bolno
Other companies: Invivyd, Inc. (Director · Since at least Sep 22, 2025)
President and Chief Executive Officer · Since at least Nov 10, 2015
Roberto Guerciolini
Other companies: Sirna Therapeutics Inc (Senior VP Development & CMO · Feb 21, 2006 – Dec 29, 2006 · Past)
See Remarks · Nov 10, 2015 – Dec 7, 2016 · Past
Aik Na TanSenior Vice President (Administration), Nanyang Technological University, Singapore · Since at least Aug 18, 2020
Chandra VargeeseSee Remarks · Since at least Nov 10, 2015
Chris FrancisSee Remarks · Since at least Nov 10, 2015
Daryn LewisSenior Vice President, Head of Human Resources · Since at least Nov 4, 2026
Erik IngelssonChief Scientific Officer · Since at least Apr 9, 2026
Ginnie YangSenior Vice President, Translational Medicine · Since at least Nov 4, 2025
Gregory L VerdineDirector · Since at least Jun 16, 2016
James SaliernoDirector, Investor Relations · Since at least Oct 27, 2026
Kate RauschVP, Corporate Affairs and Investor Relations · Since at least Oct 27, 2026
Ken TakanashiVice Chairman · Since at least Oct 7, 2026
Koji MiuraDirector · Nov 10, 2015 – Aug 15, 2019 · Past
Kyle MoranChief Financial Officer · Since at least Nov 10, 2015
Linda RockettSenior Vice President, General Counsel · Since at least Nov 4, 2026
Masaharu TanakaDirector · Aug 14, 2015 – Sep 15, 2017 · Past
Monika VnukChief Business Officer · Since at least Sep 22, 2026
Sridhar VaddeboinaSenior Vice President, Chemistry, Manufacturing, and Controls · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Wave Life Sciences Ltd.